Progenics Pharmaceuticals
(PGNX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2005 | 12-2004 | 09-2004 | 06-2004 | 03-2004 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -13,194 | -42,018 | -31,737 | -21,101 | -10,225 |
| Depreciation Amortization | 752 | 2,658 | 1,771 | 1,082 | 528 |
| Accounts receivable | 384 | -321 | -680 | -1 | 515 |
| Other Working Capital | 1,762 | -702 | -94 | -696 | -746 |
| Other Operating Activity | 254 | 3,675 | 3,228 | 1,669 | 450 |
| Operating Cash Flow | $-10,042 | $-36,708 | $-27,512 | $-19,047 | $-9,478 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 8,091 | 27,069 | 15,269 | 10,469 | 4,542 |
| PPE Investments | -264 | -2,409 | -1,423 | -923 | -542 |
| Other Investing Activity | 1 | -3 | -3 | -1 | -1 |
| Investing Cash Flow | $7,828 | $24,657 | $13,843 | $9,545 | $3,999 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 2,807 | 5,441 | 4,528 | 3,794 | 1,924 |
| Financing Cash Flow | $2,807 | $5,441 | $4,528 | $3,794 | $1,924 |
| Beginning Cash Position | 5,227 | 11,837 | 11,837 | 11,837 | 11,837 |
| End Cash Position | 5,820 | 5,227 | 2,696 | 6,129 | 8,282 |
| Net Cash Flow | $593 | $-6,610 | $-9,141 | $-5,708 | $-3,555 |
| Free Cash Flow | |||||
| Operating Cash Flow | -10,042 | -36,708 | -27,512 | -19,047 | -9,478 |
| Capital Expenditure | -264 | -2,409 | -1,423 | -923 | -542 |
| Free Cash Flow | -10,306 | -39,117 | -28,935 | -19,970 | -10,020 |